<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7493780\results\search\disease\results.xml">
  <result pre="Hsin-Bang Leu, Division of Cardiology, Department of Medicine, Taipei Veterans" exact="General" post="Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan,"/>
  <result pre="PMC, consistent with existing copyright protections.ca9-83-704.pdf Abstract The novel coronavirus" exact="disease" post="2019 (COVID-19), with first presentation of atypical pneumonia, has"/>
  <result pre="The novel coronavirus disease 2019 (COVID-19), with first presentation of" exact="atypical pneumonia," post="has spread rapidly from Wuhan, China, on December 12,"/>
  <result pre="the disease. Vulnerable patients with risk factors such as elderly," exact="cardiovascular" post="diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and"/>
  <result pre="cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and" exact="chronic" post="kidney disease have worse outcomes after COVID-19 infection. COVID-19"/>
  <result pre="diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic" exact="kidney disease" post="have worse outcomes after COVID-19 infection. COVID-19 could directly"/>
  <result pre="(eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney" exact="disease" post="have worse outcomes after COVID-19 infection. COVID-19 could directly"/>
  <result pre="have worse outcomes after COVID-19 infection. COVID-19 could directly cause" exact="cardiovascular" post="injuries such as pericarditis, myocarditis, myocardial infarction, heart failure,"/>
  <result pre="COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis," exact="myocardial infarction," post="heart failure, arrhythmias, or thromboembolic events, which urge cardiologists"/>
  <result pre="directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction," exact="heart" post="failure, arrhythmias, or thromboembolic events, which urge cardiologists to"/>
  <result pre="to practice. Here, we provide a review of COVID-19 on" exact="cardiovascular" post="system to assist clinical cardiologists to better understand the"/>
  <result pre="cardiovascular system to assist clinical cardiologists to better understand the" exact="disease" post="and being capable of providing comprehensive medical support. Cardiologists"/>
  <result pre="disease and being capable of providing comprehensive medical support. Cardiologists" exact="Cardiomyopathy" post="Cardiovascular diseases COVID-19 1. INTRODUCTION Severe acute respiratory syndrome"/>
  <result pre="comprehensive medical support. Cardiologists Cardiomyopathy Cardiovascular diseases COVID-19 1. INTRODUCTION" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV2; also known COVID-19),"/>
  <result pre="medical support. Cardiologists Cardiomyopathy Cardiovascular diseases COVID-19 1. INTRODUCTION Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV2; also known COVID-19), which"/>
  <result pre="support. Cardiologists Cardiomyopathy Cardiovascular diseases COVID-19 1. INTRODUCTION Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV2; also known COVID-19), which belongs"/>
  <result pre="Cardiologists Cardiomyopathy Cardiovascular diseases COVID-19 1. INTRODUCTION Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV2; also known COVID-19), which belongs to"/>
  <result pre="(ACE2) receptor.1 ACE2 is mainly located at human oral pharynx," exact="upper" post="airway, heart, liver, kidney, intestine, neuron, and testis. After"/>
  <result pre="currently supposed to be host defense mechanism to limit further" exact="viral" post="invasion or viral-induced mechanism to escape immune system.2 After"/>
  <result pre="critical cases.3 2. CLINICAL FEATURES OF COVID-19 COVID-19 could cause" exact="viral pneumonia," post="which may lead to respiratory failure and other extrapulmonary"/>
  <result pre="COVID-19 COVID-19 could cause viral pneumonia, which may lead to" exact="respiratory" post="failure and other extrapulmonary complications. Among those extrapulmonary complications,4â€&quot;6"/>
  <result pre="other extrapulmonary complications. Among those extrapulmonary complications,4â€&quot;6 the involvement of" exact="cardiovascular" post="system has drawn the most attention.7,8 Not only patients"/>
  <result pre="has drawn the most attention.7,8 Not only patients with preexisting" exact="cardiovascular disease" post="(CVD) have higher risk of adverse events, those without"/>
  <result pre="drawn the most attention.7,8 Not only patients with preexisting cardiovascular" exact="disease" post="(CVD) have higher risk of adverse events, those without"/>
  <result pre="without prior CVD are also vulnerable to the occurrence of" exact="cardiovascular" post="complications.5 The estimated mean incubation period for COVID-19 is"/>
  <result pre="to 14 days, with about 15% asymptomatic carrier and 85%" exact="symptomatic" post="patients. Among all patients with symptoms, 80% are mild"/>
  <result pre="mortality rate is about 3.4%, in which the comorbidity of" exact="cardiovascular disease" post="may result in 10.5% mortality rate, much higher than"/>
  <result pre="rate is about 3.4%, in which the comorbidity of cardiovascular" exact="disease" post="may result in 10.5% mortality rate, much higher than"/>
  <result pre="disease may result in 10.5% mortality rate, much higher than" exact="diabetes" post="(7.3%), chronic respiratory disease (6.3%), or no preexisting conditions"/>
  <result pre="result in 10.5% mortality rate, much higher than diabetes (7.3%)," exact="chronic" post="respiratory disease (6.3%), or no preexisting conditions (0.9%).9â€&quot;13 The"/>
  <result pre="in 10.5% mortality rate, much higher than diabetes (7.3%), chronic" exact="respiratory" post="disease (6.3%), or no preexisting conditions (0.9%).9â€&quot;13 The major"/>
  <result pre="10.5% mortality rate, much higher than diabetes (7.3%), chronic respiratory" exact="disease" post="(6.3%), or no preexisting conditions (0.9%).9â€&quot;13 The major symptoms"/>
  <result pre="congestion, diarrhea, or parageusia may also be presented initially. The" exact="viral" post="transmission and spreading could occur in asymptomatic carriers. Typical"/>
  <result pre="viral transmission and spreading could occur in asymptomatic carriers. Typical" exact="chest" post="compute tomography findings of COVID-19 are bilateral subpleural and"/>
  <result pre="asymptomatic carriers. Typical chest compute tomography findings of COVID-19 are" exact="bilateral" post="subpleural and peripheral ground-glass opacities and consolidations, which could"/>
  <result pre="chest compute tomography findings of COVID-19 are bilateral subpleural and" exact="peripheral" post="ground-glass opacities and consolidations, which could be seen in"/>
  <result pre="the patients.14 The most common lab finding of COVID-19 is" exact="lymphopenia" post="(83.2%). Other lab abnormalities similar to viral infections are"/>
  <result pre="of COVID-19 is lymphopenia (83.2%). Other lab abnormalities similar to" exact="viral" post="infections are noted such as leukopenia, thrombocytopenia, and elevated"/>
  <result pre="COVID-19 is lymphopenia (83.2%). Other lab abnormalities similar to viral" exact="infections" post="are noted such as leukopenia, thrombocytopenia, and elevated lactate"/>
  <result pre="with COVID-19 have elevated troponin levels, which indicate cardiac injury.15" exact="Acute" post="respiratory infections and respiratory system distress are recognized triggers"/>
  <result pre="COVID-19 have elevated troponin levels, which indicate cardiac injury.15 Acute" exact="respiratory" post="infections and respiratory system distress are recognized triggers for"/>
  <result pre="have elevated troponin levels, which indicate cardiac injury.15 Acute respiratory" exact="infections" post="and respiratory system distress are recognized triggers for CVD"/>
  <result pre="troponin levels, which indicate cardiac injury.15 Acute respiratory infections and" exact="respiratory" post="system distress are recognized triggers for CVD and the"/>
  <result pre="the underlying CVDs are also associated with increased severity of" exact="infectious" post="diseases.6,16â€&quot;18 3. CARDIOVASCULAR INVOLVEMENT OF COVID-19 Many patients with"/>
  <result pre="a cohort of 187 hospitalized with confirmed COVID-19 and a" exact="total" post="of 27.8% had myocardial injury as manifested by elevated"/>
  <result pre="of adhesion molecules for endothelial activation, inflammatory cell infiltration, and" exact="vascular" post="inflammation. The dysfunctional endothelium becomes proadhesive and procoagulant. The"/>
  <result pre="release procoagulant factors, such as plasminogen activator that further accelerates" exact="vascular" post="inflammation and enhances a prothrombotic state, and this is"/>
  <result pre="plasminogen activator that further accelerates vascular inflammation and enhances a" exact="prothrombotic state," post="and this is often seen with high d-dimer levels"/>
  <result pre="the cardiac tissue and also contributes to plaque rupture and" exact="acute" post="myocardial infarction.8 In addition to intracoronary plaque rupture, myocardial"/>
  <result pre="(67%) of nine patients who received coronary angiography had obstructive" exact="disease" post="and five (56%) underwent percutaneous coronary intervention (one after"/>
  <result pre="percutaneous coronary intervention (one after the administration of fibrinolytic agents.22" exact="Increased" post="troponin value represents evidence of myocardial injury and these"/>
  <result pre="hypoxic injury, coronary spasm, microthrombi, myocarditis, or true plaque rupture.20,23" exact="Severe" post="infections could cause hypoxia and hypoperfusion to vital organs"/>
  <result pre="injury, coronary spasm, microthrombi, myocarditis, or true plaque rupture.20,23 Severe" exact="infections" post="could cause hypoxia and hypoperfusion to vital organs which"/>
  <result pre="microthrombi, myocarditis, or true plaque rupture.20,23 Severe infections could cause" exact="hypoxia" post="and hypoperfusion to vital organs which predispose patient to"/>
  <result pre="of inflammation.20 From previous influenza epidemics, more patients die of" exact="cardiovascular" post="events than respiratory involvements.25 Viral infections can trigger acute"/>
  <result pre="previous influenza epidemics, more patients die of cardiovascular events than" exact="respiratory" post="involvements.25 Viral infections can trigger acute coronary syndrome, arrhythmias,"/>
  <result pre="epidemics, more patients die of cardiovascular events than respiratory involvements.25" exact="Viral" post="infections can trigger acute coronary syndrome, arrhythmias, and exacerbation"/>
  <result pre="more patients die of cardiovascular events than respiratory involvements.25 Viral" exact="infections" post="can trigger acute coronary syndrome, arrhythmias, and exacerbation of"/>
  <result pre="of cardiovascular events than respiratory involvements.25 Viral infections can trigger" exact="acute" post="coronary syndrome, arrhythmias, and exacerbation of heart failure, owing"/>
  <result pre="infections can trigger acute coronary syndrome, arrhythmias, and exacerbation of" exact="heart" post="failure, owing to combination of systemic inflammatory response and"/>
  <result pre="arrhythmias, and exacerbation of heart failure, owing to combination of" exact="systemic" post="inflammatory response and localized arterial inflammation.26,27 Systemic inflammation or"/>
  <result pre="heart failure, owing to combination of systemic inflammatory response and" exact="localized" post="arterial inflammation.26,27 Systemic inflammation or hypoxemia resulted from COVID-19"/>
  <result pre="to combination of systemic inflammatory response and localized arterial inflammation.26,27" exact="Systemic" post="inflammation or hypoxemia resulted from COVID-19 may also induce"/>
  <result pre="resulted from COVID-19 may also induce atrial/ventricular arrhythmia, most commonly" exact="atrial fibrillation," post="which may raise the issue of anticoagulants usage.28 Severe"/>
  <result pre="atrial fibrillation, which may raise the issue of anticoagulants usage.28" exact="Severe" post="inflammation could also cause hemostatic abnormalities including disseminated intravascular"/>
  <result pre="anticoagulants usage.28 Severe inflammation could also cause hemostatic abnormalities including" exact="disseminated intravascular coagulation" post="(DIC), pulmonary microthrombi formation, and intravascular coagulopathy.24 Tang et"/>
  <result pre="could also cause hemostatic abnormalities including disseminated intravascular coagulation (DIC)," exact="pulmonary" post="microthrombi formation, and intravascular coagulopathy.24 Tang et al reported"/>
  <result pre="of COVID-19 patients who died fulfilled the International Society on" exact="Thrombosis" post="and Haemostasis (ISTH) criteria for DIC, compared with only"/>
  <result pre="patients may have direct cardiac involvement including cardiomyopathy, myocarditis, or" exact="heart" post="failure. One COVID-19 case was reported to have myocarditis"/>
  <result pre="or heart failure. One COVID-19 case was reported to have" exact="myocarditis" post="with reduced systolic function and marked biventricular myocardial interstitial"/>
  <result pre="biventricular myocardial interstitial edema according to cardiac magnetic resonance images.30" exact="Sporadic" post="autopsy cases also showed infiltration of interstitial mononuclear inflammatory"/>
  <result pre="within myocardium.31 Endomyocardial biopsy done in a COVID-19 patient with" exact="cardiogenic shock" post="showed viral particles in the myocardium, suggesting the damages"/>
  <result pre="biopsy done in a COVID-19 patient with cardiogenic shock showed" exact="viral" post="particles in the myocardium, suggesting the damages could either"/>
  <result pre="treatment choices or consideration focus on treatment related to the" exact="cardiovascular" post="field. 4.1. Antiviral therapies Remdesivir (GS-5734), adenosine analogue, is"/>
  <result pre="active form GS-441524 and thereafter interferes with the action of" exact="viral" post="RNA-dependent RNA polymerase, resulting a in decrease in viral"/>
  <result pre="of viral RNA-dependent RNA polymerase, resulting a in decrease in" exact="viral" post="RNA production. Remdesivir was effective against various types of"/>
  <result pre="A preliminary data also showed that remdesivir also inhibited SARS-CoV-2" exact="infection" post="efficiently in a human cell line.33 Remdesivir was provided"/>
  <result pre="evaluate the effect of remdesivir in COVID-19 patients with different" exact="disease" post="severity (https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials). Lopinavir and ritonavir were two protease inhibitor"/>
  <result pre="ritonavir were two protease inhibitor which was used to treat" exact="HIV infection." post="In a randomized, controlled, open-label trial involving hospitalized adult"/>
  <result pre="HIV infection. In a randomized, controlled, open-label trial involving hospitalized" exact="adult" post="patients with confirmed COVID-19 and high oxygen demand, patients"/>
  <result pre="in addition to standard care or standard care alone. The" exact="primary" post="end point was the time to clinical improvement, defined"/>
  <result pre="from the hospital. Although the results showed no benefit on" exact="primary" post="endpoint and the detectable viral load were also similar"/>
  <result pre="results showed no benefit on primary endpoint and the detectable" exact="viral" post="load were also similar between the two groups, there"/>
  <result pre="One of the known adverse cardiac effects of lopinavir/ritonavir is" exact="hyperlipidemia" post="and the potential prolongation of QT and PR intervals"/>
  <result pre="warning of US FDA in 2009. Antiviral drugs for influenza" exact="infection" post="were also tested. Oseltamivir showed little effect on COVID-19"/>
  <result pre="Favipiravir showed better therapeutic responses on COVID-19 in terms of" exact="disease" post="progression and viral clearance in an experimental trial.38 In"/>
  <result pre="therapeutic responses on COVID-19 in terms of disease progression and" exact="viral" post="clearance in an experimental trial.38 In a prospective, randomized,"/>
  <result pre="trial.38 In a prospective, randomized, controlled, open-label multicenter trial involving" exact="adult" post="patients with COVID-19, patients were randomly assigned in a"/>
  <result pre="conventional therapy plus umifenovir or favipiravir for 10 days. The" exact="primary" post="outcome was clinical recovery rate of day 7. The"/>
  <result pre="interactions with antiplatelet agents and anticoagulants in patients with prior" exact="cardiovascular disease." post="Medications now in investigation of COVID-19 treatment such as"/>
  <result pre="that were metabolized by CYP3A4 should be cautious when P2Y12" exact="Platelet" post="receptor inhibitors used simultaneously in patients with cardiovascular disease.24"/>
  <result pre="when P2Y12 Platelet receptor inhibitors used simultaneously in patients with" exact="cardiovascular" post="disease.24 4.2. Chloroquine/hydroxychloroquine Evidences suggested that the antimalarial drugs"/>
  <result pre="pH of the endosome, which prevents cathepsin-induced priming of the" exact="viral" post="S protein. In vitro study showed both chloroquine and"/>
  <result pre="hydroxychloroquine was associated with a significant difference in clearing of" exact="viral" post="nasopharyngeal carriage of SARS-CoV2 within 3 to 6 days"/>
  <result pre="system (RAS) that is expressed on the cell surface of" exact="type 2" post="alveolar epithelial cells in the lungs and other tissues."/>
  <result pre="is expressed on the cell surface of type 2 alveolar" exact="epithelial" post="cells in the lungs and other tissues. It also"/>
  <result pre="increase the severity of COVID-19, especially in patients with existing" exact="cardiovascular" post="diseases. However, the experimental and clinical data showed conflicting"/>
  <result pre="experimental and clinical data showed conflicting results. Experimental models of" exact="acute" post="lung injury, including a model of SARS-CoV infection, suggest"/>
  <result pre="suggest that ARBs may mitigate COVID-19 by attenuating Ang IIâ€&quot;mediated" exact="acute" post="lung injury by blocking AT1R.46 RAAS inhibitors on ACE2"/>
  <result pre="from clinical or animal study showing that ACEI/ARB use increase" exact="cardiovascular" post="complication. Therefore, the ACC/AHA statement suggested the ACEI/ARB use"/>
  <result pre="results showed inpatient use of ACEI/ARB in COVID-19 patients with" exact="hypertension" post="was associated with lower risk of all-cause mortality compared"/>
  <result pre="of ACEI/ARB in COVID-19 patients with hypertension was associated with" exact="lower" post="risk of all-cause mortality compared with non-users.48 Paired trials"/>
  <result pre="hospitalized (NCT04311177). 4.4. Antiplatlet/anticoagulation A large portion of patient with" exact="cardiovascular" post="comorbidities in patient with COVID-19 and a significant number"/>
  <result pre="COVID-19 and a significant number of patients would have received" exact="cutaneous" post="coronary interventions. Thrombocytopenia, prolonged thrombin time, and elevated d-dimer"/>
  <result pre="SARS and COVID-19, suggestive of high likelihood of DIC. Also," exact="diffuse" post="alveolar hemorrhage (DAH) was reported as a common finding"/>
  <result pre="patients. The safety concerns about antiplatelet therapy (DAPT) on life-threatening" exact="bleeding" post="complications among COVID-19 should be addressed. Evidences suggested that"/>
  <result pre="suggested that prehospital use of aspirin use was associated a" exact="lower" post="risk of for developing ARDS and mortality in patients"/>
  <result pre="showed encouraging clinical benefit of ticagrelor in the management of" exact="pneumonia" post="by preventing the complications of sepsis and reducing lung"/>
  <result pre="for patients at low, intermediate, and high risk for both" exact="ischemia" post="and bleeding.52 Zhou et al suggested among patients with"/>
  <result pre="thromboembolic risks which include endothelial damage, microvascular thrombosis/occlusion, and even" exact="autoimmune" post="mechanisms. Coagulopathy is known to occur in the majority"/>
  <result pre="with low molecular weight heparin appeared to be associated with" exact="lower" post="mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or"/>
  <result pre="be associated with lower mortality in the subpopulation meeting sepsis-induced" exact="coagulopathy" post="criteria or with markedly elevated d-dimer. Currently statements suggest"/>
  <result pre="of anticoagulation therapy. 4.5. Statins Patients with comorbidities including hypertension," exact="cardiovascular" post="diseases, and diabetes tend to have higher risk for"/>
  <result pre="4.5. Statins Patients with comorbidities including hypertension, cardiovascular diseases, and" exact="diabetes" post="tend to have higher risk for having severe COVID-19"/>
  <result pre="have higher risk for having severe COVID-19 which leads to" exact="acute" post="respiratory distress syndrome (ARDS) and mortality.55 Statins are commonly"/>
  <result pre="higher risk for having severe COVID-19 which leads to acute" exact="respiratory" post="distress syndrome (ARDS) and mortality.55 Statins are commonly prescribed"/>
  <result pre="for having severe COVID-19 which leads to acute respiratory distress" exact="syndrome" post="(ARDS) and mortality.55 Statins are commonly prescribed in most"/>
  <result pre="in most of the patients with CVDs according to current" exact="diabetes" post="and cardiovascular guidelines. Statins are known to have anti-inflammatory"/>
  <result pre="of the patients with CVDs according to current diabetes and" exact="cardiovascular" post="guidelines. Statins are known to have anti-inflammatory effects which"/>
  <result pre="trial, a post hoc analysis showed a reduction in incident" exact="pneumonia" post="with rosuvastatin.59 Currently there is no evidence to determine"/>
  <result pre="statin therapy should be continued in patients with suspected COVID-19" exact="infection" post="with existing cardiovascular comorbidities since no evidence show harmful"/>
  <result pre="be continued in patients with suspected COVID-19 infection with existing" exact="cardiovascular" post="comorbidities since no evidence show harmful and acute cardiac"/>
  <result pre="with existing cardiovascular comorbidities since no evidence show harmful and" exact="acute" post="cardiac injury could also occur in COVID-19. Adverse effects"/>
  <result pre="effects of statin should still be monitored since myalgia, increased" exact="creatine phosphokinase," post="rhabdomyolysis, and acute kidney injury do occur in patients"/>
  <result pre="still be monitored since myalgia, increased creatine phosphokinase, rhabdomyolysis, and" exact="acute" post="kidney injury do occur in patients with COVID-19.15 Also,"/>
  <result pre="be monitored since myalgia, increased creatine phosphokinase, rhabdomyolysis, and acute" exact="kidney injury" post="do occur in patients with COVID-19.15 Also, drug-drug interactions"/>
  <result pre="like to be treated with anti-arrhythmic drugs whether due to" exact="disease" post="progression or existing comorbidities. Amiodarone, a widely used antiarrhythmic"/>
  <result pre="of SARS coronavirus. In vitro study showed amiodarone inhibited SARS-CoV" exact="infection" post="and spreading via altering the late compartments of the"/>
  <result pre="of prophylactic intravenous amiodarone to mitigate the risk of late" exact="sudden cardiac arrest" post="among patients infected with the novel COVID-19 had been"/>
  <result pre="prophylactic intravenous amiodarone to mitigate the risk of late sudden" exact="cardiac arrest" post="among patients infected with the novel COVID-19 had been"/>
  <result pre="COVID-19 had been suggested.63 4.5. Colchicine Patients with severe COVID-19" exact="infection" post="have higher serum levels of pro-inflammatory cytokines (tumor necrosis"/>
  <result pre="and IL-6) and chemokines (IL-8) compared with individuals with mild" exact="disease" post="or healthy controls. In experimental models, it has been"/>
  <result pre="a major pathophysiological component in the development of ARDS and" exact="acute" post="lung injury. The simulated structural models have shown that"/>
  <result pre="has been successfully used in two cases of life-threatening posttransplant" exact="capillary leak syndrome," post="which mechanism also involves cytokine release.66 Colchicine has been"/>
  <result pre="performed for evaluating the effect of colchicine on the COVID-19" exact="infection" post="(NCT NCT04326790, NCT04322682). In conclusion, the understanding of the"/>
  <result pre="patients, health care workers, and health systems during the coronavirus" exact="disease" post="2019 (COVID-19) pandemic.J Am Coll Cardiol2020;75:2352â€&quot;71.32201335 5.ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiAet al.Coronavirus disease"/>
  <result pre="coronavirus disease 2019 (COVID-19) pandemic.J Am Coll Cardiol2020;75:2352â€&quot;71.32201335 5.ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiAet al.Coronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular disease.Circulation2020;141:1648â€&quot;55.32200663 6.MadjidMSafavi-NaeiniPSolomonSDVardenyOPotential effects of coronaviruses"/>
  <result pre="pandemic.J Am Coll Cardiol2020;75:2352â€&quot;71.32201335 5.ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiAet al.Coronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="disease.Circulation2020;141:1648â€&quot;55.32200663 6.MadjidMSafavi-NaeiniPSolomonSDVardenyOPotential effects of coronaviruses on the cardiovascular system:"/>
  <result pre="(COVID-19) and cardiovascular disease.Circulation2020;141:1648â€&quot;55.32200663 6.MadjidMSafavi-NaeiniPSolomonSDVardenyOPotential effects of coronaviruses on the" exact="cardiovascular" post="system: a review.JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1286. 7.BonowROFonarowGCOâ€™GaraPTYancyCWAssociation of coronavirus disease 2019"/>
  <result pre="on the cardiovascular system: a review.JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1286. 7.BonowROFonarowGCOâ€™GaraPTYancyCWAssociation of coronavirus" exact="disease" post="2019 (COVID-19) with myocardial injury and mortality.JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1105. 8.LiuPPBletASmythDLiHThe"/>
  <result pre="and mortality.JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1105. 8.LiuPPBletASmythDLiHThe science underlying COVID-19: implications for the" exact="cardiovascular" post="system.Circulation2020;142:68â€&quot;78.32293910 9.YangXYuYXuJShuHXiaJLiuHet al.Clinical course and outcomes of critically ill"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study.Lancet Respir"/>
  <result pre="wave of SARS-CoV-2?Lancet2020;395:947. 13.BackerJAKlinkenbergDWallingaJIncubation period of 2019 novel coronavirus (2019-nCoV)" exact="infections" post="among travellers from Wuhan, China.Euro Surveill2020;25:2000062. 14.HosseinyMKoorakiSGholamrezanezhadAReddySMyersLRadiology perspective of"/>
  <result pre="among travellers from Wuhan, China.Euro Surveill2020;25:2000062. 14.HosseinyMKoorakiSGholamrezanezhadAReddySMyersLRadiology perspective of coronavirus" exact="disease" post="2019 (COVID-19): lessons from severe acute respiratory syndrome and"/>
  <result pre="14.HosseinyMKoorakiSGholamrezanezhadAReddySMyersLRadiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe" exact="acute" post="respiratory syndrome and middle east respiratory syndrome.AJR Am J"/>
  <result pre="perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute" exact="respiratory" post="syndrome and middle east respiratory syndrome.AJR Am J Roentgenol2020;214:1â€&quot;5.31860355"/>
  <result pre="of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory" exact="syndrome" post="and middle east respiratory syndrome.AJR Am J Roentgenol2020;214:1â€&quot;5.31860355 15.GuanWJNiZYHuYLiangWHOuCQHeJXet"/>
  <result pre="(COVID-19): lessons from severe acute respiratory syndrome and middle east" exact="respiratory" post="syndrome.AJR Am J Roentgenol2020;214:1â€&quot;5.31860355 15.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus"/>
  <result pre="respiratory syndrome.AJR Am J Roentgenol2020;214:1â€&quot;5.31860355 15.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China.N Engl J Med2020; 382:1708â€&quot;20.32109013 16.MadjidMMillerCCZarubaevVVMarinichIGKiselevOILobzinYVet al.Influenza"/>
  <result pre="in China.N Engl J Med2020; 382:1708â€&quot;20.32109013 16.MadjidMMillerCCZarubaevVVMarinichIGKiselevOILobzinYVet al.Influenza epidemics and" exact="acute" post="respiratory disease activity are associated with a surge in"/>
  <result pre="China.N Engl J Med2020; 382:1708â€&quot;20.32109013 16.MadjidMMillerCCZarubaevVVMarinichIGKiselevOILobzinYVet al.Influenza epidemics and acute" exact="respiratory" post="disease activity are associated with a surge in autopsy-confirmed"/>
  <result pre="Engl J Med2020; 382:1708â€&quot;20.32109013 16.MadjidMMillerCCZarubaevVVMarinichIGKiselevOILobzinYVet al.Influenza epidemics and acute respiratory" exact="disease" post="activity are associated with a surge in autopsy-confirmed coronary"/>
  <result pre="respiratory disease activity are associated with a surge in autopsy-confirmed" exact="coronary heart disease" post="death: results from 8 years of autopsies in 34,892"/>
  <result pre="disease activity are associated with a surge in autopsy-confirmed coronary" exact="heart" post="disease death: results from 8 years of autopsies in"/>
  <result pre="activity are associated with a surge in autopsy-confirmed coronary heart" exact="disease" post="death: results from 8 years of autopsies in 34,892"/>
  <result pre="death: results from 8 years of autopsies in 34,892 subjects.Eur" exact="Heart" post="J2007;28:1205â€&quot;10.17440221 17.CowanLTLutseyPLPankowJSMatsushitaKIshigamiJLakshminarayanKInpatient and outpatient infection as a trigger of"/>
  <result pre="of autopsies in 34,892 subjects.Eur Heart J2007;28:1205â€&quot;10.17440221 17.CowanLTLutseyPLPankowJSMatsushitaKIshigamiJLakshminarayanKInpatient and outpatient" exact="infection" post="as a trigger of cardiovascular disease: The ARIC Study.J"/>
  <result pre="Heart J2007;28:1205â€&quot;10.17440221 17.CowanLTLutseyPLPankowJSMatsushitaKIshigamiJLakshminarayanKInpatient and outpatient infection as a trigger of" exact="cardiovascular" post="disease: The ARIC Study.J Am Heart Assoc2018;7:e009683.30571501 18.DhainautJFClaessensYEJanesJNelsonDRUnderlying disorders"/>
  <result pre="as a trigger of cardiovascular disease: The ARIC Study.J Am" exact="Heart" post="Assoc2018;7:e009683.30571501 18.DhainautJFClaessensYEJanesJNelsonDRUnderlying disorders and their impact on the host"/>
  <result pre="20.GuoTFanYChenMWuXZhangLHeTet al.Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19).JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1017. 21.BhatrajuPKGhassemiehBJNicholsMKimRJeromeKRNallaAKet al.COVID-19 in critically ill patients"/>
  <result pre="birds and men: cardiologistsâ€™ role in influenza pandemics.Lancet2004;364:1309. 26.MadjidMAboshadyIAwanILitovskySCasscellsSWInfluenza and" exact="cardiovascular" post="disease: is there a causal relationship?Tex Heart Inst J2004;31:4â€&quot;13.15061620"/>
  <result pre="pandemics.Lancet2004;364:1309. 26.MadjidMAboshadyIAwanILitovskySCasscellsSWInfluenza and cardiovascular disease: is there a causal relationship?Tex" exact="Heart" post="Inst J2004;31:4â€&quot;13.15061620 27.VardenyOSolomonSDInfluenza vaccination: a one-shot deal to reduce"/>
  <result pre="Heart Inst J2004;31:4â€&quot;13.15061620 27.VardenyOSolomonSDInfluenza vaccination: a one-shot deal to reduce" exact="cardiovascular" post="events.Eur Heart J2017;38:334â€&quot;7.27856498 28.WangEYHulmeOLKhurshidSWengLCChoiSHWalkeyAJet al.Initial precipitants and recurrence of"/>
  <result pre="J2004;31:4â€&quot;13.15061620 27.VardenyOSolomonSDInfluenza vaccination: a one-shot deal to reduce cardiovascular events.Eur" exact="Heart" post="J2017;38:334â€&quot;7.27856498 28.WangEYHulmeOLKhurshidSWengLCChoiSHWalkeyAJet al.Initial precipitants and recurrence of atrial fibrillation.Circ"/>
  <result pre="Thromb Haemost2020;18:844â€&quot;7.32073213 30.InciardiRMLupiLZacconeGItaliaLRaffoMTomasoniDet al.Cardiac involvement in a patient with coronavirus" exact="disease" post="2019 (COVID-19).JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1096. 31.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated"/>
  <result pre="2019 (COVID-19).JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1096. 31.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome.Lancet Respir Med2020;8:420â€&quot;2.32085846 32.TavazziGPellegriniCMaurelliMBelliatoMSciuttiFBottazziAet al.Myocardial localization of"/>
  <result pre="(COVID-19).JAMA Cardiol2020Doi:10.1001/jamacardio.2020.1096. 31.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome.Lancet Respir Med2020;8:420â€&quot;2.32085846 32.TavazziGPellegriniCMaurelliMBelliatoMSciuttiFBottazziAet al.Myocardial localization of coronavirus"/>
  <result pre="32.TavazziGPellegriniCMaurelliMBelliatoMSciuttiFBottazziAet al.Myocardial localization of coronavirus in COVID-19 cardiogenic shock.Eur J" exact="Heart" post="Fail2020;22:911â€&quot;5.32275347 33.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and chloroquine effectively inhibit the recently"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China.JAMA2020;323:1061â€&quot;9.32031570 37.DongLHuSGaoJDiscovering drugs to treat coronavirus disease"/>
  <result pre="coronavirus-infected pneumonia in Wuhan, China.JAMA2020;323:1061â€&quot;9.32031570 37.DongLHuSGaoJDiscovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19).Drug Discov Ther2020;14:58â€&quot;60.32147628 38.CaiQYangMLiuDChenJShuDXiaJet al.Experimental treatment with favipiravir"/>
  <result pre="COVID-19: a randomized clinical trial.medRxiv. 2020Doi:10.1101/2020.03.17.20037432. 40.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on" exact="viral" post="infections: an old drug against todayâ€™s diseases?Lancet Infect Dis2003;3:722â€&quot;7.14592603"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2).Clin Infect Dis2020Doi:10.1093/cid/ciaa237. 42.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2).Clin Infect Dis2020Doi:10.1093/cid/ciaa237. 42.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2).Clin Infect Dis2020Doi:10.1093/cid/ciaa237. 42.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and azithromycin"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies.Biosci Trends2020;14:72â€&quot;3.32074550 44.PrincipiNEspositoSChloroquine or hydroxychloroquine for prophylaxis"/>
  <result pre="and angiotensin II receptor blockers with mortality among patients with" exact="hypertension" post="hospitalized with COVID-19.Circ Res. 2020Doi:10.1161/CIRCRESAHA.120.317134. 49.SextonTRZhangGMacaulayTECallahanLACharnigoRVsevolozhskayaOAet al.Ticagrelor reduces thromboinflammatory"/>
  <result pre="patients with pneumonia.JACC Basic Transl Sci2018;3:435â€&quot;49.30175268 50.StoreyRFJamesSKSiegbahnAVarenhorstCHeldCYcasJet al.Lower mortality following" exact="pulmonary" post="adverse events and sepsis with ticagrelor compared to clopidogrel"/>
  <result pre="findings.Circulation2020;141:1736â€&quot;8.32298134 54.ThachilJTangNGandoSFalangaACattaneoMLeviMet al.ISTH interim guidance on recognition and management of" exact="coagulopathy" post="in COVID-19.J Thromb Haemost2020;18:1023â€&quot;6.32338827 55.WuCChenXCaiYXiaJaZhouXXuSet al.Risk factors associated with"/>
  <result pre="coagulopathy in COVID-19.J Thromb Haemost2020;18:1023â€&quot;6.32338827 55.WuCChenXCaiYXiaJaZhouXXuSet al.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients With coronavirus"/>
  <result pre="in COVID-19.J Thromb Haemost2020;18:1023â€&quot;6.32338827 55.WuCChenXCaiYXiaJaZhouXXuSet al.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients With coronavirus disease"/>
  <result pre="Thromb Haemost2020;18:1023â€&quot;6.32338827 55.WuCChenXCaiYXiaJaZhouXXuSet al.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients With coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients With coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China.JAMA Intern Med2020Doi:10.1001/jamainternmed.2020.0994. 56.FrostFJPetersenHTollestrupKSkipperBInfluenza and"/>
  <result pre="distress syndrome and death in patients With coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China.JAMA Intern Med2020Doi:10.1001/jamainternmed.2020.0994. 56.FrostFJPetersenHTollestrupKSkipperBInfluenza and COPD mortality"/>
  <result pre="study.J Infect Dis2012;205:13â€&quot;9.22170954 58.CalfeeCSDelucchiKLSinhaPMatthayMAHackettJShankar-HariMet al.collab: Irish Critical Care Trials Group." exact="Acute respiratory distress syndrome" post="subphenotypes and differential response to simvastatin: secondary analysis of"/>
  <result pre="Infect Dis2012;205:13â€&quot;9.22170954 58.CalfeeCSDelucchiKLSinhaPMatthayMAHackettJShankar-HariMet al.collab: Irish Critical Care Trials Group. Acute" exact="respiratory" post="distress syndrome subphenotypes and differential response to simvastatin: secondary"/>
  <result pre="58.CalfeeCSDelucchiKLSinhaPMatthayMAHackettJShankar-HariMet al.collab: Irish Critical Care Trials Group. Acute respiratory distress" exact="syndrome" post="subphenotypes and differential response to simvastatin: secondary analysis of"/>
  <result pre="Acute respiratory distress syndrome subphenotypes and differential response to simvastatin:" exact="secondary" post="analysis of a randomised controlled trial.Lancet Respir Med2018;6:691â€&quot;8.30078618 59.NovackVMacFadyenJMalhotraAAlmogYGlynnRJRidkerPMThe"/>
  <result pre="pneumonia.medRxiv2020Doi:10.1101/2020.02.24.20027052. 63.StadlerKHaHRCiminaleVSpirliCSalettiGSchiavonMet al.Amiodarone alters late endosomes and inhibits SARS coronavirus" exact="infection" post="at a post-endosomal level.Am J Respir Cell Mol Biol2008;39:142â€&quot;9.18314540"/>
  <result pre="dysregulation.Med Hypotheses2016;92:67â€&quot;73.27241260 66.CocchiEChialeFGianoglioBDeorsolaLPace NapoleoneCFagioliFet al.Colchicine: an impressive effect on posttransplant" exact="capillary leak syndrome" post="and renal failure.Pediatrics2019;143:e20182820.31000685 67.MisawaTTakahamaMKozakiTLeeHZouJSaitohTet al.Microtubule-driven spatial arrangement of mitochondria"/>
  <result pre="66.CocchiEChialeFGianoglioBDeorsolaLPace NapoleoneCFagioliFet al.Colchicine: an impressive effect on posttransplant capillary leak" exact="syndrome" post="and renal failure.Pediatrics2019;143:e20182820.31000685 67.MisawaTTakahamaMKozakiTLeeHZouJSaitohTet al.Microtubule-driven spatial arrangement of mitochondria"/>
 </snippets>
</snippetsTree>
